Traduction de «Size scale » (Anglais → Français) :

Question No. 53 Ms. Kirsty Duncan: With respect to the chronic cerebrospinal venous insufficiency (CCSVI) clinical trial being undertaken by Dr. Traboulse: (a) what milestones are reportable to the government, (i) on what date(s) is reporting expected to occur, (ii) how will this information be communicated to patients, the medical community, and the general public; (b) on what date did each of the trial sites pass ethical review; (c) on what date did recruitment of patients begin for each of the trial sites; (d) how many patients with multiple sclerosis (MS) are being recruited for each site, and how is consistency in diagnosis and treatment being ensured across sites; (e) who is performing the diagnoses for CCSVI for each site, (i) ho ...[+++]w is the diagnosis being performed, including, but not limited to, ultrasound and venogram, (ii) how many diagnoses has each person undertaking the diagnosis at each site performed prior to the study, and by whom was each person trained; (f) who is performing the procedures for each site, (i) how is the procedure being performed, including, but not limited to, anesthetic, balloon size, (ii) how many procedures has each person undertaking the procedure at each site performed prior to the study, and by whom was each person trained; (g) what are the selection criteria for the trial, including, but not limited to, type of MS, Expanded Disability Status Scale (EDSS) score, venous abnormality/malformed valve/stenosis, mobility, (i) how do these criteria compare with the international literature, (ii) with how many international studies to date will the selection criteria be analytically comparable; (h) if both progressive and relapsing-remitting forms of MS are to be examined in the trial, how will statistical significance be ensured given that 50 of 100 patients will undergo a “sham” procedure, 25 patients will have a progressive form of the disease, and 25 will have a relapsing-remitting form of the disease, and will people with bo ...

However, there are serious discrepancies between the Member States in terms of technological progress, market size, scale of production and fuel market structures.

However, there are serious discrepancies between the Member States in terms of technological progress, market size, scale of production and fuel market structures.

A quoting obligation is imposed for all transactions except those which are large in scale compared to normal market size (Normal market size in a share could be well above €3m, as it's defined on some securities markets in the EU.) One plausible interpretation is that the Council text would require firms to quote publicly in any size of trade that they were actually carrying out, unless the trades were “large in scale compared to normal market size”.

I am aware of the scale of this challenge, given both the size and complexity of the issue itself and the number and diversity of the parties affected by it, inside and outside Parliament.

The figures in the table show that there is no simple relationship between the size of the scientific base – measured in terms of publication output – and the scale of funding policies.